The acquisition gives BiomEdit control of Folium’s Guided Biotics CRISPR-Cas technology and BiomElix One.
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines.